OTC Markets EXMKT - Delayed Quote USD

Idorsia Ltd (IDRSF)

Compare
1.0500
0.0000
(0.00%)
As of April 3 at 4:00:00 PM EDT. Market Open.
Currency in CHF All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
74,122
152,386
97,102
35,349
71,758
Cost of Revenue
16,520
7,150
6,266
--
--
Gross Profit
57,602
145,236
90,836
35,349
--
Operating Expense
451,004
688,290
893,800
648,353
482,341
Operating Income
-393,402
-543,054
-802,964
-613,004
-410,583
Net Non Operating Interest Income Expense
-30,322
-39,107
-17,124
-21,802
-38,697
Pretax Income
-295,436
-294,253
-820,089
-634,805
-449,279
Tax Provision
992
3,668
7,807
-210
-4,160
Net Income Common Stockholders
-296,428
-297,921
-827,896
-634,595
-444,791
Diluted NI Available to Com Stockholders
-296,428
-297,921
-827,896
-634,595
-444,791
Basic EPS
-1.65
-1.67
-4.67
-3.77
-3.11
Diluted EPS
-1.65
-1.67
-4.67
-3.77
-3.11
Basic Average Shares
179,951.6220
178,246.8720
177,433.9340
168,498.0480
142,809.0720
Diluted Average Shares
179,951.6220
178,246.8720
177,433.9340
168,498.0480
142,809.0720
Total Operating Income as Reported
-265,113
-255,145
-802,965
-613,004
-410,582
Total Expenses
467,524
695,440
900,066
648,353
482,341
Net Income from Continuing & Discontinued Operation
-296,428
-297,921
-827,896
-634,595
-444,791
Normalized Income
-413,811.5200
-561,355.9050
-827,896
-634,595
-444,791
Interest Expense
19,459
20,668
17,172
27,937
9,717
Net Interest Income
-30,322
-39,107
-17,124
-21,802
-38,697
EBIT
-275,977
-273,585
-802,917
-606,868
-439,562
EBITDA
-258,350
-254,551
-783,088
-588,835
-420,637
Reconciled Cost of Revenue
16,520
7,150
6,266
--
--
Reconciled Depreciation
17,627
19,034
19,829
18,033
18,925
Net Income from Continuing Operation Net Minority Interest
-296,428
-297,921
-827,896
-634,595
-444,791
Total Unusual Items Excluding Goodwill
128,288
287,907
--
--
--
Total Unusual Items
128,288
287,907
--
--
--
Normalized EBITDA
-386,638
-542,458
-783,088
-588,835
-420,637
Tax Rate for Calcs
0.0001
0.0001
0.0001
0
0
Tax Effect of Unusual Items
10,904.4800
24,472.0950
--
--
--
12/31/2020 - 7/17/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

OXB.L Oxford Biomedica plc
263.50
-2.77%
 
PRAX Praxis Precision Medicines, Inc.
32.59
-2.13%
 
NUVL Nuvalent, Inc.
66.16
-3.16%
 
HRMY Harmony Biosciences Holdings, Inc.
29.25
-5.55%
 
STOK Stoke Therapeutics, Inc.
5.89
-6.59%
 
BPMC Blueprint Medicines Corporation
83.49
-4.16%
 
KROS Keros Therapeutics, Inc.
9.93
-3.40%
 
INCY Incyte Corporation
62.20
-0.42%
 
LQDA Liquidia Corporation
13.30
-5.87%
 
MNPR Monopar Therapeutics Inc.
29.85
-13.70%